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Introduction
The extent and diversity of mycobacterial disease is a global problem, impacting significantly both on human and animal health. Mycobacterium tuberculosis is a Gram-positive pathogen that is the main aetiological agent of tuberculosis (TB), and recent statistics from the World Health Organization (WHO) estimate that there were 9.27 million incident cases of TB in 2007 [1] .
Furthermore, with an estimated 500 000 multidrug-resistant TB (MDR-TB) cases and at least one case of extensively-drug-resistant TB (XDR-TB) reported in 55 countries and territories by the end of 2008 [1] , the identification and development of novel antimicrobial compounds is now more important than ever. However, with the exception of rifabutin and rifapentine, no novel drugs have been marketed for TB in the 40 years following the release of rifampicin [2] . An additional worry is the increasing number of pathogenic mycobacteria other than M. tuberculosis, which are being implicated as causative agents of disease [3] , especially in acquired immune deficiency syndrome (AIDS) patients. One such species, Mycobacterium avium subsp. paratuberculosis (MAP), the aetiological agent of Johne's disease in animals, has caused significant controversy, with reports suggesting its association with Crohn's disease in humans [4] [5] [6] . Another mycobacterium, Mycobacterium kansasii, is responsible for serious pulmonary infections and some non-life threatening infections such as septic arthritis [7] .
In recent years, an enhanced appreciation of the efficacy of the antimicrobials known as lantibiotics has resulted in their being the focus of much attention as a possible M a n u s c r i p t 4 alternative to current antibiotic regimens [8] [9] [10] [11] [12] [13] [14] . Lantibiotics are gene-encoded, posttranslationally-modified antimicrobial peptides [8] that are distinguished by the unusual lanthionine and/or -methyllanthionine residues, dehydrated serines and/or threonines [8] . To date, more than 50 different lantibiotics have been identified with different structures and modes of action [13] , and recent comprehensive reviews on lantibiotics have highlighted their potential therapeutic applications [12] [13] [14] .
Nisin A and lacticin 3147 are two of the most extensively characterised lantibiotics.
Nisin is the prototypical lantibiotic and has been approved by the US Food and Drug Administration (FDA) for use in food and veterinary products [15] . Lacticin 3147 differs from nisin by virtue of requiring two peptides for optimal activity, i.e. Ltn and Ltn (formerly LtnA1 and LtnA2) [16] . Notably, both nisin and lacticin 3147 are active at nanomolar concentrations [16] and can inhibit antibiotic-resistant bacteria [17] .
Moreover, both antimicrobials possess more than one mechanism of action in that they inhibit peptidoglycan synthesis as well as forming pores in the membrane of target cells. Both activities are facilitated by binding to the peptidoglycan precursor, lipid II [18] [19] [20] [21] , which is also a target for some conventional antimycobacterials such as rifampicin that require transportation across the plasma membrane before they can be effective [22] . It is notable that the structure of mycobacterial lipid II differs from all other structures in bacteria investigated to date. This is due to an alternative synthesis pathway as well as modifications both on the N-acetylmuramic acid and peptide side chain components [23] . Peptidoglycan synthesis in mycobacteria is depicted in Fig. 1 .
A c c e p t e d M a n u s c r i p t 5 Whilst nisin has been found to be active against non-pathogenic Mycobacterium smegmatis and Mycobacterium bovis strains [24] , neither nisin nor lacticin 3147 have been comprehensively assessed with respect to their antimicrobial activity against clinically significant human and animal mycobacterial pathogens.
Materials and methods

Mycobacterium strains and culture conditions
Mycobacterium kansasii CIT11/06 (10 days) and M. tuberculosis H37Ra (11 days) were routinely grown at 37 C in Middlebrook 7H9GC broth (MB) (Sigma-Aldrich, Arklow, Co. Wicklow, Ireland) supplemented with glycerol (0.2%) and 10% oleic acid-albumin-dextrose-catalase (OADC) (Unitech, Dublin, Ireland). MAP ATCC 19698, also grown in MB containing OADC, was supplemented with 0.2% mycobactin J (Synbiotics Europe, Lyon, France) and was incubated at 37 C for 8-12 weeks. All strains were stocked in 40% glycerol and stored at -80 C.
Preparation of pure lacticin 3147 and nisin A
The lantibiotics were purified as described previously [17, 25] . In brief, peptides were concentrated via centrifugation and rotary evaporation before being applied to a Phenomenex C12 reversed-phase high-performance liquid chromatography (RP-HPLC) column (Phenomenex, Cheshire, UK) equilibrated with 25% propan-2-ol and 0.1% trifluoroacetic acid (TFA). The column was subsequently developed in a Page 6 of 24 A c c e p t e d M a n u s c r i p t 6 gradient of 30% propan-2-ol containing 0.1% TFA to 60% propan-2-ol containing 0.1% TFA at a flow rate of 1.2 mL/min.
Preparation of mycobacterial cells
Owing to the slow-growing nature of pathogenic mycobacteria, standard agar and broth minimum inhibitory concentration (MIC) assay methods could not be performed routinely. Thus, the reliable and established microtitre alamarBlue assay was employed [26] [27] [28] . Isolates of M. kansasii, MAP and M. tuberculosis were grown in MB as described above. At log phase, a 10 mL culture of each mycobacterial strain was centrifuged at 15 000 rpm for 20 min using a benchtop centrifuge. Following removal of the supernatant, the pellet was washed in fresh MB and re-suspended in 10 mL of fresh supplemented MB. The turbidity was adjusted to match a McFarland standard no. 1 (3  10 8 colony-forming units/mL) with MB. A further 1:20 dilution of the culture was then performed in MB to generate a sufficient volume of culture.
Determination of minimum inhibitory concentrations against clinical isolates using the microtitre alamarBlue assay
Sterile deionised water (300 L) was added to all outer-perimeter wells of a 96-well plate to minimise evaporation of the medium in the test wells during incubation. In Oxford, UK) was added to each well and the plates were re-incubated for 24 h, after which time absorbance at 570 nm and 600 nm was determined. Subsequent percent reduction values based on alamarBlue conversion were determined using the appropriate formula [29] and the relative growth in each well was compared with that of the positive control. The MIC 90 was defined as the lowest concentration of lantibiotic that prevented the growth of >90% of the bacterial population relative to the positive control.
Results
AlamarBlue-based minimum inhibitory concentration determination
AlamarBlue is a redox indicator that yields a colorimetric change in a response to metabolic activity [28] . Relative inhibition of mycobacteria by nisin and lacticin 3147
was assessed by quantifying the absorbance (570 nm and 600 nm) of all wells to facilitate the calculation of dye reduction values (%) using the appropriate formula [29] . Wells that remained blue (i.e. low dye reduction values) were indicative of inhibition of the target strain, whilst wells that turned pink (high dye reduction values)
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MIC 90 values for nisin and lacticin 3147 against Mycobacterium kansasii CIT11/06
Of the strains tested, M. kansasii CIT11/06 was the least susceptible to lacticin 3147, with an MIC 90 value of 60 mg/L (Table 1 ; Fig. 3 ). Relative growth inhibition was 93% at this concentration (Fig. 3) . Below 15 mg/L, the potency of lacticin 3147 became significantly decreased. However, even at the lowest concentration of lacticin 3147 employed (0.11 mg/L), activity was still apparent as represented by a 29.2%
inhibition of M. kansasii (Fig. 3 ).
In comparison, nisin was more active against M. kansasii CIT11/06 than the other strains tested, with an MIC 90 value of 60 mg/L. At this concentration, 94.5% inhibition of M. kansasii growth was noted. This dropped to 67.5% inhibition at 30 mg/L nisin and, as expected, even further for the lower concentrations. However, even at the lowest concentration of nisin tested (0.11 mg/L), inhibitory activity was still detected (30.3% inhibition) (Fig. 3) .
MIC 90 values for nisin and lacticin 3147 against Mycobacterium avium paratuberculosis ATCC 19698
For lacticin 3147, the MIC 90 for MAP ATCC 19698 was 15 mg/L (90.6% reduction) ( Table 1 ; Fig. 4) . Moreover, 95.2% and 94% inhibition of the MAP population was recorded at concentrations of 60 mg/L and 30 mg/L, respectively, whilst strong inhibition (86%) was also observed when 7.5 mg/L lacticin 3147 was utilised (Fig. 4) . M a n u s c r i p t
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At the lowest concentration employed (0.11 mg/L), lacticin 3147 successfully inhibited >50% of the MAP population.
Although nisin showed quite good efficacy against MAP, 60 mg/L nisin failed to bring about 90% inhibition, with inhibition peaking at 81% (Fig. 4) . A decrease in efficacy was seen with lower concentrations of nisin, with moderate activity still apparent at very low concentrations (0.46-0.11 mg/L) (Fig. 4) .
Comparison of the relative antimycobacterial activities of lacticin 3147 and nisin
Under these experimental conditions, lacticin 3147 consistently showed superior activity at higher concentrations (Table 1) . Mycobacterium tuberculosis was the most susceptible species of mycobacteria, particularly to lacticin, which was 8 times more potent than nisin (Fig. 2) . Lacticin 3147 brought about as much as 38% greater inhibition at equivalent concentrations compared with nisin (7.5 mg/L). Whilst this difference in relative growth remained relatively constant between the concentrations of 15-7.5 mg/L, below 0.93 mg/L both nisin and lacticin 3147 had an equivalent inhibitory effect against M. tuberculosis.
Lacticin 3147 also exhibited superior potency against M. kansasii (Fig. 3) , with 31% less relative growth in the presence of lacticin 3147 compared with nisin (15 mg/L).
Although the MIC 90 values for both lantibiotics were the same, the general trend of inhibition indicated that lacticin 3147 was more potent. However, at concentrations <1.8 mg/L, the activity of both lantibiotics was comparable.
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Lacticin 3147 also displayed strong inhibitory activity against MAP, with an MIC 90 value 4-fold lower than that of nisin (15 mg/L and <60 mg/L, respectively) (Fig. 4) .
As with the other two strains, both lantibiotics had similar inhibitory capacity at lower concentrations (e.g. 0.11 mg/L). The greatest difference in percent relative growth between both lantibiotics at equivalent concentrations was seen between 15 mg/L and 3.75 mg/L. This relative difference remained almost constant over these three concentrations (23.6-24.6% relative growth).
Discussion
Antimicrobial peptides are rapidly becoming a realistic alternative therapy, with many peptides showing potent activity against pathogens that has led to their evaluation in clinical trials [30] . Although lantibiotics are traditionally associated with food applications [31] , it is evident from the literature that they possess notable levels of activity against clinical pathogens [17, [32] [33] [34] [35] [36] . However, this study is notable in that it is the first occasion upon which the efficacy of lacticin 3147 against a Mycobacterium sp. has been tested and compared with the activity of nisin. It is also significant that the mycobacteria chosen for this study (which are implicated both in human and animal disease) showed considerable susceptibility to both agents. This study also establishes lipid II as a promising antimycobacterial target and confirms that binding of lantibiotics to the mycobacterial lipid II is not compromised by the extensively modified lipid II structure in mycobacteria [23] .
Of the two lantibiotics, lacticin 3147 demonstrated greater potential as a therapeutic agent. This can be attributed to its activity at physiological pH 7, which contrasts with M a n u s c r i p t 12 that of nisin that is poorly soluble, and thus less active, at this pH [8, 36] . The lower activity of nisin at physiological pH has reportedly also been an issue with respect to its use in the treatment of mastitis-causing pathogens [8] . From the data presented here, it is apparent that lacticin 3147 inhibits mycobacteria at concentrations that are comparable with those of antibiotics currently employed against these pathogens [37, 38] . These values are in some cases superior to those of the first-line antimycobacterial drug isoniazid that had MIC values of 4-16 mg/L as determined by
Wanger and Mills [37] .
Whilst the in vitro efficacy of lacticin 3147 against mycobacteria is encouraging, stability, delivery and in vivo efficacy studies will all need to proceed before the true potential of the lantibiotic as a clinical antimycobacterial can be assessed. The unique ability of some mycobacteria to reside in the phagosomal site within pulmonary macrophages makes their eradication extremely difficult. Moreover, the delivery of antimycobacterial agents that traverse the plasma membrane and maintain stability and activity is rare. However, recent studies have demonstrated that administration of bacteriocins as a complex with liposomes provides a successful mechanism of delivery and inhibition, thus prolonging survival time of mice in an acute TB model [39] . In this context, lantibiotics undoubtedly possess sufficient potential to merit further investigation.
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